Research programme: anti-tau antibodies - AC Immune/Genentech

Drug Profile

Research programme: anti-tau antibodies - AC Immune/Genentech

Latest Information Update: 14 Jan 2014

Price : $50

At a glance

  • Originator AC Immune
  • Developer AC Immune; Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Neurodegenerative disorders

Most Recent Events

  • 09 Jan 2014 Preclinical development is ongoing
  • 18 Jun 2012 AC Immune's anti-tau antibodies licensed to Genentech worldwide for the treatment of Alzheimer's disease and other neurodegenerative disorders
  • 31 Oct 2009 Preclinical development for Alzheimer's disease and other Neurodegenerative disorders in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top